aflibercept – Medxy AI

Evaluating Aflibercept With Reduced-Fluence Photodynamic Therapy in Polypoidal Choroidal Vasculopathy: Insights from Longitudinal OCT Angiography

By MedXY 10/09/2026

This randomized trial compares aflibercept monotherapy versus combined with reduced-fluence photodynamic therapy for PCV, highlighting OCTA metrics that predict polypoidal lesion closure and treatment response over 52 weeks.

Clinical Updates news Ophthalmology

Outcomes of As-Needed Aflibercept Treatment After Complete Regression in Polypoidal Choroidal Vasculopathy: A Clinical Review

By MedXY 09/22/2026

This review synthesizes evidence on PRN aflibercept treatment after complete polypoidal regression in PCV, highlighting recurrence rates, visual outcomes, and potential OCT biomarkers guiding individualized management.

news Ophthalmology

Biodegradable Aflibercept Microsphere‑Hydrogel Shows Long‑Term Ocular Biocompatibility in Rhesus Macaques

By MedXY 11/03/2025

A biodegradable PLGA microsphere–thermo‑responsive hydrogel delivering aflibercept was well tolerated after single intravitreal injection in 23 rhesus macaques with preserved retinal structure and function up to 24 months.